1. PATHWAY-2: spironolactone for resistant hypertension – Authors' reply
Bryan Williams, Tom M MacDonald, Steven V Morant, Morris J Brown 
The Lancet 
Volume 387, Issue 10026, Pages (April 2016)
DOI: /S (16)00698-X
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure
Home systolic and diastolic blood pressures comparing spironolactone with each of the other drugs
The top of each column represents the unadjusted home systolic blood pressures and the bottom of each column shows the diastolic blood pressures. The striped bars represent measurements at the midcycle at 6 weeks (low dose) and the solid bars represent end-of-cycle at 12 weeks (high dose) measurements in which patients received the drug. Error bars represent 95% CI. *Comparison is between spironolactone versus the combined average of doxazosin and bisoprolol.
The Lancet  , DOI: ( /S (16)00698-X)
Copyright © 2016 Elsevier Ltd Terms and Conditions